-
Mashup Score: 2
CAN-3110, an HSV-1 oncolytic viral immunotherapy candidate, has received FDA fast track designation for adult patients with recurrent high-grade glioma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2SRS Reduces Cognitive Decline in Those With Brain Metastases - 4 month(s) ago
Findings from a secondary analysis of a phase 3 trial support stereotactic radiosurgery as a standard of care for those with brain metastases, although whole-brain radiotherapy may yield more local and distant control.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
The use of SRS correlated with less cognitive decline compared with postoperative WBRT in patients with cancer and brain metastases, although the latter resulted in an improvement in intracranial tumor control. #btsm | @joshuapalmermd https://t.co/6edh1wQbOL https://t.co/rDYX94bOP5
-
-
Mashup Score: 1Michael Strahan’s Daughter Reveals Cancer Diagnosis, Defense Secretary Hospitalized After Cancer Surgery and More - 4 month(s) ago
From Michael Strahan announcing his cancer diagnosis to a “Baywatch” star being diagnosed with cancer, here’s what’s happening in the oncology space this week.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Last week, @michaelstrahan announced that his daughter received a cancer diagnosis. Read about that and more. #BTSM https://t.co/waPJdxqlkB
-
-
Mashup Score: 1Tafinlar Plus Mekinist Shows Benefits In Pediatric Glioma - 5 month(s) ago
A recent phase 2 trial revealed that the combination of Tafinlar and Mekinist benefitted children with BRAF-mutated low-grade gliomas.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Tafinlar plus Mekinist demonstrates promising benefits. #BTSM https://t.co/1dvK0dBhCU
-
-
Mashup Score: 1
The FDA has set a Prescription Drug User Fee Act date of April 30, 2024 for tovorafenib as a treatment for pediatric patients with relapsed or progressive low-grade glioma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
Supporting data for the NDA came from the phase 2 FIREFLY-1 trial assessing tovorafenib in patients with relapsed or progressive pediatric low-grade glioma. #btsm | @US_FDA @FDAOncology https://t.co/3V1GJxHN8R
-
-
Mashup Score: 0
The FDA has granted fast track designation to the investigational vaccine SurVaxM for the treatment of patients with newly diagnosed glioblastoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
FDA Grants Fast Track Designation to SurVaxM in Newly Diagnosed Glioblastoma @us_fda #btsm https://t.co/SzqKvGEROC
-
-
Mashup Score: 0
TUESDAY, Oct. 17, 2023 (HealthDay News) — Americans born in recent years can likely count on taking prescription drugs for about half their life, according to new research.For males born in 2019, it’s about 48% of their lives. For women, it’s 60% of their lifetime, the study found.“The years that p…
Source: consumer.healthday.comCategories: Latest Headlines, Oncologists1Tweet-
“The desire to take medicine is perhaps the greatest feature which distinguishes man from animals.” - Sir William Osler. #Oncology #BCSM #LCSM #BTSM #GynCSM #MedOnc #RadOnc #Urology #GynOnc #Cancer #PanCan #PCSM https://t.co/dznbqJNnrz
-
-
Mashup Score: 0Pachymeningeal disease: a systematic review and metanalysis - 7 month(s) ago
Journal of Neuro-Oncology – Pachymeningeal disease (PMD) is a newly recognized pattern of brain metastasis (BrM) failure that specifically occurs following surgery with adjuvant stereotactic…
Source: link.springer.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gutierrez-Valencia et al uncover Pachymeningeal Disease (PMD) as a complication following Stereotactic Radiosurgery. PMD has a better prognosis than Leptomeningeal Disease (LMD). Early recognition is crucial. #BTSM #JNO #neurooncology #braintumor https://t.co/v3HAX7qTOm https://t.co/yaiTW4WIfr
-
-
Mashup Score: 0
The FDA has granted fast track designation to the investigational vaccine SurVaxM for the treatment of patients with newly diagnosed glioblastoma.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The FDA has granted fast track designation to the investigational vaccine SurVaxM for the treatment of patients with newly diagnosed glioblastoma. @us_fda #btsm https://t.co/SzqKvGEROC
-
-
Mashup Score: 0FDA Panel Votes Sufficient Evidence Available to Support EFS Benefit of Eflornithine in Pediatric High-Risk Neuroblastoma - 7 month(s) ago
In a 14-to-6 vote, the FDA’s Oncologic Drugs Advisory Committee voted sufficient evidence has been provided to demonstrate the event-free survival benefit of eflornithine to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The NDA for eflornithine was supported by data from the phase 2 Study 3b trial and an external control arm of patients with high-risk neuroblastoma in the phase 3 ANBL0032 trial. @US_FDA @ChildrensNatl @ChildrensLA @KECKSchool_USC @RoswellPark #btsm https://t.co/tT5ENhMZ7a https://t.co/7t02KrCbUp
-
.@us_fda Grants Fast Track Designation to CAN-3110 for Recurrent High-Grade Glioma @EAChiocca @BrighamWomens @Harvardmed #btsm https://t.co/rDeetQiwRO